Patent ID: 8389688

Claim:
A monoclonal humanized anti-CD22 antibody comprising a heavy chain variable region (“VH”) and a light chain variable region (“VL”), wherein (a) the heavy chain variable region comprises three complementarity determining regions (“CDRs”), VH CDR1, VH CDR2, and VH CDR3, and four framework regions (“FWs”), VH FW1, VH FW2, VH FW3, and VH FW4, in the order VH FW1, VH CDR1, VH FW2, VH CDR2, VH FW3, VH CDR3, and VH FW4, wherein VH CDR1 comprises the amino acid sequence DYGVN (SEQ ID NO:62), VH CDR2 comprises the amino acid sequence IIWGDGRTDYNSALKS (SEQ ID NO:63), and VH CDR3 comprises the amino acid sequence APGNRAMEY (SEQ ID NO:64); and wherein (i) VH FW1 comprises the amino acid sequence QVQLEESGGGVVRPGRSLRLSCAASGFTFD (SEQ ID NO:80), or (ii) VH FW1 comprises the amino acid sequence QVQLEESGGGVVRPGRSLRLSCAASGFTLS (SEQ ID NO:83), VH FW2 comprises the amino acid sequence WIRQAPGKGLEWVG (SEQ ID NO:85), and VH FW3 comprises the amino acid sequence RLTVSRNNSNNTLSLQMNSLTTEDTAVYYCVR (SEQ ID NO:87); and (b) the light chain variable region comprises three complementarity determining regions, VL CDR1, VL CDR2, and VL CDR3, and four framework regions, VL FW1, VL FW2, VL FW3, and VL FW4, in the order VL FW1, VL CDR1, VL FW2, VL CDR2, VL FW3, VL CDR3, and VL FW4; wherein VL CDR1 comprises the amino acid sequence KASQSVTNDVA (SEQ ID NO:65), VL CDR2 comprises the amino acid sequence YASNRYT (SEQ ID NO:66), and VL CDR3 comprises the amino acid sequence QQDYRSPWT (SEQ ID NO:67).